Peripheral Blood CD34+ Percentage at Hematological Recovery after Chemotherapy Is a Good Early Predictor of Harvest: A Single-Center Experience
Open Access
- 1 May 2014
- journal article
- clinical trial
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 20 (5) , 717-723
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-StratificationTransplantation and Cellular Therapy, 2014
- Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilizationBone Marrow Transplantation, 2012
- Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or LymphomaTransplantation and Cellular Therapy, 2012
- How I treat patients who mobilize hematopoietic stem cells poorlyBlood, 2011
- A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixaforBone Marrow Transplantation, 2011
- Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoBone Marrow Transplantation, 2011
- Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilizationBone Marrow Transplantation, 2010
- Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use dataBone Marrow Transplantation, 2010
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaBlood, 2009
- AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use dataBone Marrow Transplantation, 2007